Reduction of Vascular Inflammation, LDL-C, or Both for the Protection from Cardiovascular Events?
The Open Cardiovascular Medicine Journal · 30.03.2018 · 12 (1) · 29-40
DOI: 10.2174/1874192401812010029 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Open Cardiovascular Medicine Journal, erschienen am 30.03.2018. Verfasst von Andromachi Reklou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippocration Hospital, Thessaloniki, Greece. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Low density lipoprotein cholesterol (LDL-C) and low grade arterial inflammation are key pathogenic factors for atherosclerosis and its manifestation, cardiovascular disease (CVD).
Objective
In this narrative review we assessed if decreasing LDL-C levels or inflammation or both is more effective in reducing CVD events.
Results
In the Scandinavian Simvastatin Survival Study (4S), all statin trials of the 90s’ and the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) the benefit came from the LDL-C reduction. In the GREak and Atorvastatin Coronary heart disease Evaluation (GREACE), the Treating to New Targets (TNT), and the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trials both mechanisms in combination produced significant benefits. In the Atorvastatin for Reduction of MYocardial Damage during Angioplasty (ARMYDA) trials and the Canakinumab Antiinflammatory Thrombosis Outcome Study (CANTOS) with a human antibody targeting IL-1β with no lipid lowering effect, the reduction in arterial inflammation played the only beneficial role because there was no change in lipids levels.
Conclusion
Both LDL-C and inflammation reduction are beneficial to the reduction of CVD risk. However, canakinumab is a very expensive drug that only induced a 15% reduction in CVD events, thus drastically reducing the possibility for it to be used in clinical practice. Besides, canakinumab is associated with increased infections, some fatal. A potent statin with anti-inflammatory effects is probably the best choice for the majority of those needing hypolipidaemic drug therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippocration Hospital, Thessaloniki, Greece.
- George Washington University, Washington, DC, USA.
Zitieren
APA
Reklou, A., Doumas, M., Imprialos, K., Stavropoulos, K., Patoulias, D., & Athyros, V. G. (2018). Reduction of Vascular Inflammation, LDL-C, or Both for the Protection from Cardiovascular Events?. The Open Cardiovascular Medicine Journal, 12(1), 29-40. https://doi.org/10.2174/1874192401812010029
Vancouver
Reklou A, Doumas M, Imprialos K, Stavropoulos K, Patoulias D, Athyros VG. Reduction of Vascular Inflammation, LDL-C, or Both for the Protection from Cardiovascular Events?. The Open Cardiovascular Medicine Journal. 2018;12(1):29-40. doi:10.2174/1874192401812010029
BibTeX
@article{Reklou2018,
author = {Reklou, Andromachi and Doumas, Michael and Imprialos, Konstantinos and Stavropoulos, Konstantinos and Patoulias, Dimitris and Athyros, Vasilios G},
title = {Reduction of Vascular Inflammation, LDL-C, or Both for the Protection from Cardiovascular Events?},
journal = {The Open Cardiovascular Medicine Journal},
year = {2018},
volume = {12},
number = {1},
pages = {29--40},
doi = {10.2174/1874192401812010029}
}
EUVIMED